LexinFintech Holdings (NASDAQ:LX) Bolsa

LexinFintech Holdings

LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.

Movers_Stocks

AAOI

AFYA

AKBA

BTBT

CVNA

DOCU

FUTU

GDOT

QBTS

RBRK

RDUS

RGNX

RGTI

SMTC

SOUN

ULTA

Semtech sorprendió al mercado con ingresos y ganancias superiores a lo esperado. Inversores reaccionan ante este sólido desempeño trimestral.

Semtech, Rubrik, DocuSign, PagerDuty y otras acciones estadounidenses que suben el viernes

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

APCX

Descubre por qué LexinFintech (LX) y AppTech Payments (APCX) están lanzando señales de advertencia a los inversores.

Acciones sobrecompradas en el sector financiero: LexinFintech y AppTech Payments

LexinFintech Holdings Ltd. - American Depositary Shares

LexinFintech Holdings Ltd

Lux Amber Corp

Lixiang Education Holding Co., Ltd. - American Depositary Shares

Lixiang Education Holding Co Ltd

LITHIUM ENERGI EXPL INC by Lithium Energi Exploration Inc.

Lithium Energi Exploration Inc

Lexeo Therapeutics Inc

Luxfer Holdings PLC

LEXINGTON BIOSCIENCES by Lexington Biosciences Inc

Registered Plan Private Investments Inc

LXI REIT PLC by LXI REIT PLC

Eureka 93 Inc

LOXLEY PCL NVDR by Loxley Public Co., Ltd.

Loxley PCL

LXP Industrial Trust Common Stock (Maryland REIT)

LXP Industrial Trust

LXP Industrial Trust 6.5% Series C Cumulative Convertible Preferred Stock

LUXOR AS B by LUXOR AS

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals Inc

LSB Industries Inc

Lexagene Holdings Inc

LUXEY INTL HLDGS LTD by LUXEY INTL HLDGS LTD.

Wells Fargo analyst Ike Boruchow upgrades Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) from Equal-Weight to Overweight and lowers the price target from $275 to $240.

Upgrades

Price Target

Analyst Ratings

Wells Fargo Upgrades Ralph Lauren to Overweight, Lowers Price Target to $240

Wells Fargo analyst Alec Brondolo upgrades Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) from Underweight to Equal-Weight and raises the price target from $169 to $176.

Wells Fargo Upgrades Wix.com to Equal-Weight, Raises Price Target to $176

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) with a Buy and maintains $24 price target.

Reiteration

TRVI

Needham Reiterates Buy on Trevi Therapeutics, Maintains $24 Price Target

Standard Chartered on Tuesday forecasted that XRP&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) market capitalization will overtake Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) by the end of 2028, positioning XRP as the <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">second-largest non-stablecoin digital asset</a>.
What Happened: The bold prediction, made by Geoffrey Kendrick, head of digital assets research at Standard Chartered, highlights XRP's growing role in cross-border payments amid shifting market dynamics.
The announcement coincides with the New York Stock Exchange's approval of a new leveraged XRP exchange-traded fund, signaling increased mainstream interest in the cryptocurrency.
In a note shared with Benzinga, Kendrick emphasized XRP's potential to outpace Ethereum over the next few years.
"By the end of 2028 we see XRP's market cap overtaking Ethereum's," he wrote, attributing the shift to XRP's core utility as a platform for cross-border and cross-currency payments. 
He noted that this segment of the digital asset market is experiencing a sustained increase in transaction volumes, a trend Standard Chartered expects to persist, bolstering XRP's value proposition.
Kendrick's analysis positions XRP alongside Bitcoin and Avalanche as top performers in the digital asset space, while identifying Ethereum as a relative underperformer. 
"XRP's core use is as a cross-border and cross-currency payments platform," Kendrick stated, underscoring its practical application as a key driver of its projected growth. 
He added that Bitcoin's resilience during recent market turbulence, including global tariff concerns, suggests a broader upward trajectory for cryptocurrencies, with XRP poised to benefit significantly.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44681738/bitcoin-is-a-more-liquid-and-higher-volatility-version-of-gold-bernstein">Bitcoin Is A &#8216;More Liquid And Higher Volatility Version Of Gold&#8217;: Bernstein</a>
Why It Matters: The prediction comes as XRP gains traction in traditional financial markets.
The NYSE approved the Teucrium 2x Long Daily XRP ETF (XXRP), set to launch on April 8.
This leveraged ETF, designed to deliver twice XRP's daily price performance through swap contracts, marks a milestone as the first XRP-tied ETF in the U.S. 
Unlike spot ETFs, it does not hold XRP directly but tracks its daily movements, offering investors an alternative entry point into the asset's price action. 
Following the news, XRP's price rose approximately 11%, reaching $1.96, according to Coingecko data.
Kendrick urged investors to remain focused on long-term opportunities despite short-term volatility. "Keep looking for winners and HODLing those you already own. 
Tariff mess will be over soon, and Bitcoin's solid performance during the noise tells us a leg higher for the asset class will follow," he advised. 
The bank's outlook reflects confidence in XRP's ability to capitalize on its niche in facilitating efficient international transactions, a use case that sets it apart from Ethereum's broader focus on smart contracts and decentralized applications.
While no spot XRP ETF has been approved in the U.S., the Securities and Exchange Commission has acknowledged several filings this year, suggesting regulatory progress. 
Bloomberg ETF analyst Eric Balchunas said on the unusual nature of a leveraged ETF preceding a spot product, noting that it's a rare occurrence in the digital asset space. 
The XXRP fund carries an annual expense ratio of 1.85%, reflecting the costs of its derivative-based strategy.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44672506/blackrock-ceo-larry-fink-warns-many-already-believe-the-us-is-in-a-recession">BlackRock CEO Larry Fink Warns &#8216;Many Already Believe The US Is In A Recession&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$XRP

XRP Will Overtake Ethereum By 2028: Standard Chartered

Wells Fargo analyst John Kilichowski upgrades Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) from Equal-Weight to Overweight and maintains the price target from $158 to $158.

WELL

Wells Fargo Upgrades Welltower to Overweight, Maintains Price Target to $158

Needham analyst Ami Fadia reiterates Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) with a Buy and maintains $59 price target.

RVMD

Needham Reiterates Buy on Revolution Medicines, Maintains $59 Price Target

CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) on Tuesday named Brian Newman as executive vice president and chief financial officer designate, effective&nbsp;April 21.
He will succeed current chief financial officer Tom&nbsp;Cowhey, who will transition as a strategic advisor to president and chief executive officer&nbsp;David Joyner, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44680644/cvs-health-announces-chief-financial-officer-transition-plan-appoints-chief-medical-officer" rel="noreferrer noopener">effective&nbsp;May 12</a>.
Newman was most recently executive vice president and chief financial officer of United Parcel Service Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44627279/ftc-pauses-lawsuit-against-cvs-cigna-unitedhealths-pbms-amid-commissioner-shortage" rel="noreferrer noopener">FTC Pauses Lawsuit Against CVS, Cigna, UnitedHealth's PBMs Amid Commissioner Shortage</a>
Before joining UPS, Newman spent 26 years with PepsiCo, where he held finance leadership roles across&nbsp;Europe,&nbsp;Asia, and North and&nbsp;South America. He also served as executive vice president for PepsiCo's global operations and chief strategy officer. Newman began his career as an investment banker at PaineWebber.
Amy Compton-Phillips, the company's new executive vice president and chief medical officer, effective&nbsp;May 19, will also report to David&nbsp;Joyner.
Dr. Compton-Phillips was most recently chief physician executive of Press Ganey, a health care performance improvement company.
Prior to Press Ganey, Dr. Compton-Phillips was the president and chief clinical officer at Providence Health &amp; Services, a health care system, responsible for clinical operations and care including improving health, care, and value outcomes delivered by the system's hospitals, clinics, and caregivers. From 1985 to 2007, she held positions of increasing responsibility at Kaiser Permanente.
In February, CVS Health reported fourth-quarter sales of $97.71 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43709040/cvs-health-gains-momentum-after-q4-performance-analyst-upgrades-stock" rel="noreferrer noopener">consensus of $97.19 billion</a>.
Total revenues increased 4.2%, driven by growth in the Health Care Benefits and Pharmacy &amp; Consumer Wellness segments, partially offset by a decline in the&nbsp;Health Services segment.
The Medical benefit ratio increased from 88.5% to 94.8% compared to the prior year, driven by increased utilization, the unfavorable impact of the previously disclosed decline in the company's Medicare Advantage star ratings for the 2024 payment year, and the impact of higher acuity in Medicaid.
In October 2024, CVS Health&nbsp;appointed longtime executive&nbsp;David Joyner as its new president and CEO, replacing&nbsp;Karen Lynch amid the company's&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo" rel="noreferrer noopener">ongoing financial struggles</a>.
In November 2024, CVS&nbsp;Health appointed Prem&nbsp;Shah as the Group President, responsible for the operational performance across CVS Caremark, CVS Pharmacy, and the company's&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769048/cvs-health-announces-leadership-appointments" rel="noreferrer noopener">Healthcare Delivery businesses</a>.
In addition, the company appointed Steve Nelson&nbsp;as President of Aetna.
Price Action: At the last check on Tuesday, CVS stock was up 9.52% at $69.93 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/forex/25/04/44680574/global-markets-rebound-in-relief-rally-gold-back-to-3000" target="_blank" rel="noreferrer noopener">Global Markets Rebound In Relief Rally, Gold Back To $3,000</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

Management

Movers

General

CVS Health Appoints Former UPS And Pepsi Exec As Finance Chief, Stock Soars

WIIM

AVGO

Broadcom shares are trading higher after the company authorized a $10 billion share repurchase authorization.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Shares of health insurers are trading higher following a WSJ report indicating the Trump administration will increase Medicare Advantage rates.

Wells Fargo analyst Ike Boruchow upgrades Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) from Equal-Weight to Overweight and raises the price target from $140 to $150.

ROST

Wells Fargo Upgrades Ross Stores to Overweight, Raises Price Target to $150

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $72 price target.

CYTK

Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

Bear markets, defined as a drop of 19.9% or greater from their previous high, tend to be significantly more severe and prolonged when they occur in conjunction with a recession, according to an investment strategist.
What Happened: According to analysis shared by Liz Ann Sonders, Chief Investment Strategist at Charles Schwab, &#8220;Bear markets tend to be larger and longer when they're associated with recessions.&#8221;
In a recent post on X, Sonders shared a compelling scatter plot showcasing this relationship using S&amp;P 500 bear market data spanning from 1946 to April 4, 2025. The chart shows bear markets that coincided with recessions and the bear markets that did not.
Bear markets occurring without a recession have historically been shallower and shorter in duration. These instances have a mean drawdown of 30%, spanning between 200 to 250 days. This magnitude and duration are shorter compared to their recession-linked counterparts.
The red circles on the chart, representing bear markets intertwined with economic recessions, are generally clustered towards the bottom-right quadrant. The mean drawdown for such instances shows more than 30% of correction, spanning nearly 400 days.
Notable historical examples like the 2000-2002 tech bubble burst and the 2007-2009 Global Financial Crisis, both accompanied by recessions, saw substantial drawdowns and extended periods of recovery. The longest instance of such a market accompanied by recession was in 1973, which lasted for about 650 days, pulling the index down nearly 50%.
The chart reinforces Sonders&#8217; core message: the presence of a recession acts as a significant amplifier of bear market pain and its longevity.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bear markets tend to be larger and longer when they're associated with recessions ⁦<a href="https://twitter.com/nberpubs?ref_src=twsrc%5Etfw">@nberpubs</a>⁩ <a href="https://t.co/ghzFLTwV9W">pic.twitter.com/ghzFLTwV9W</a>
&mdash; Liz Ann Sonders (@LizAnnSonders) <a href="https://twitter.com/LizAnnSonders/status/1909526087052165433?ref_src=twsrc%5Etfw">April 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/25/04/44679385/market-enters-risk-off-mode-as-analyst-predicts-this-signal-flashing-warnings-similar-to-2020-and-2008-crisis">Market Enters &#8216;Risk-Off&#8217; Mode As Analyst Predicts This Signal Flashing Warnings Similar To 2020, 2008 Crisis</a>
Why It Matters: While past performance is no guarantee of future results, this historical analysis provides valuable context for investors navigating the current economic landscape.
Understanding the historical relationship between bear markets and recessions can help investors better assess potential risks and adjust their investment strategies accordingly. Following President Donald Trump&#8216;s tariff announcements last Wednesday, markets saw two straight days of losses on Thursday and Friday before closing mixed on Monday, intensifying the recent selloff.
As of Monday, only the Nasdaq 100 index was in the bear market territory, down by 21.56% from its previous high of 22,222.61 points. The S&amp;P 500 was nearing the bear market zone as it was 17.65% below its previous record high of 6,147.43 points. The Dow Jones, on the other hand, was down by 15.77% from its 52-week high of 45,073.63 points.
Goldman Sachs has further <a href="https://www.benzinga.com/25/04/44662991/goldman-sachs-raises-risk-of-recession-to-45-jefferies-calls-tariffs-a-free-hall-pass-for-tech-giants-to-reset-their-goals">increased its U.S. recession</a> forecast to 45% (from 35% on Sunday), citing tighter financial conditions and policy uncertainty, echoing <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy?_gl=1&#x2A;1mnei8t&#x2A;_gcl_au&#x2A;NzQyMjgxNjUuMTczNzYwNzI4NQ..&#x2A;_ga&#x2A;ZGVsZXRlZA..&#x2A;_ga_V7ZK73W7N0&#x2A;MTc0NDAyMzE1Ny4yNDYuMS4xNzQ0MDIzMjMyLjAuMC4w">JPMorgan&#8217;s 60% global recession</a> odds from last week. However, Jefferies analysts propose that these very headwinds, including Trump&#8217;s tariffs, might give tech companies leeway to adjust their financial guidance.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, advanced in premarket on Tuesday. The SPY was up 2.53% to $517.15, while the QQQ advanced 2.49% to $434.23 according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44678610/volatility-gauge-vix-spikes-118-in-3-days-tops-45-for-2nd-day-first-time-since-gfc-and-pandemic" target="_blank" rel="noreferrer noopener">Volatility Gauge VIX More Than Doubles In 3 Days: Crosses The 45 Mark For 2nd Day, 1st Time Since 2008 Financial Crisis</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Government

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

ETFs

Bear Markets Hit Harder And Last Longer During Recessions, Says Market Strategist: Here's A Historical Look At Bear Market Severity And Duration

William Blair analyst Lachlan Brown initiates coverage on Kalaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLRS#NASDAQ">KLRS</a>) with a Outperform rating.

Initiation

KLRS

William Blair Initiates Coverage On Kalaris Therapeutics with Outperform Rating

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $5 price target.

ESPR

Needham Reiterates Buy on Esperion Therapeutics, Maintains $5 Price Target

FDA Grants SeaStar Medical Two New Breakthrough Device Designations For Its Selective Cytopheretic Device Therapy

CYCU

Cycurion shares are trading higher after the company announced an expanded partnership with Journal Technologies and a $22 million multi-year contract with a state police agency.

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/07/final-trades-berkshire-hathaway-first-citizens-bancshares-and-kla-corp.html">Halftime Report Final Trades</a>,&#8221; Brian Belski of BMO Capital Markets named First Citizens Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) as his <a href="https://www.benzinga.com/quote/FCNCA/earnings">final trade</a>.
On the earnings front, First Citizens will report its financial results for the quarter that ended March 31, before the opening bell on Thursday, April 24. 
Analysts expect the firm to report quarterly earnings at $37.87 per share, down from $52.92 per share in the year-ago period. The company projects quarterly revenue of $2.22 billion, compared to $2.29 billion a year earlier.
Jim Lebenthal of Cerity Partners picked Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>).
The Wall Street Journal reported last month that Compass was in talks to buy Warren Buffett&#8216;s <a href="https://www.benzinga.com/ma/25/03/44317138/warren-buffetts-real-estate-brokerage-compass-discuss-deal-report">real estate brokerage unit</a>.
Don't forget to check out our<a href="https://www.benzinga.com/premarket/"> premarket coverage here</a>
Jason Snipe of Odyssey Capital Advisors named KLA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>).
Morgan Stanley analyst Shane Brett supported his view on March 31, upgrading KLA&#8217;s rating from Equal-Weight to Overweight and raising the price target from $748 to $870.
Price Action:
<ul>
<li>First Citizens Bancshares shares gained 2.2% to close at $1,606.17 on Monday.</li>
<li>Berkshire Hathaway shares fell 0.6% to close at $490.38 during Monday's session.</li>
<li>KLA shares gained 4.9% to settle at $604.62 on Monday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44669062/top-3-health-care-stocks-that-may-crash-in-q2">Top 3 Health Care Stocks That May Crash In Q2</a></li>
</ul>
Image: Shutterstock

Media

FCNCA

KLAC

First Citizens Bancshares, Berkshire Hathaway And A Tech Stock On CNBC's 'Final Trades'

William Blair analyst Lachlan Brown initiates coverage on Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Outperform rating.

OCUL

William Blair Initiates Coverage On Ocular Therapeutix with Outperform Rating

Biotech

RLYB

Rallybio to Discontinue Development Of RLYB212 In Prevention Of FNAIT, Says RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy

<a href="https://www.wsj.com/business/deals/janus-henderson-strikes-deal-to-manage-45-billion-of-insurers-assets-4de6b4de" title="https://www.wsj.com/business/deals/janus-henderson-strikes-deal-to-manage-45-billion-of-insurers-assets-4de6b4de">https://www.wsj.com/business/deals/janus-henderson-strikes-deal-to-manage-45-billion-of-insurers-assets-4de6b4de</a>

Contracts

Janus Henderson Group plc Ordinary Shares

Janus Enters Partnership With Guardian Life To Manage $45B And Develop New Products, Executives Say

Press Releases

LexinFintech Holdings Ltd. to Report First Quarter 2024 Unaudited Financial Results on May 23, 2024

Earnings

LexinFintech Holdings Ltd. Reports First Quarter 2024 Unaudited Financial Results

LexinFintech Holdings Ltd. to Report Second Quarter 2024 Unaudited Financial Results on August 27, 2024

LexinFintech Holdings Ltd. Reports Second Quarter 2024 Unaudited Financial Results

LexinFintech Holdings Ltd. to Report Third Quarter 2024 Unaudited Financial Results on November 25, 2024

LexinFintech Holdings Ltd. Reports Third Quarter 2024 Unaudited Financial Results

LexinFintech Holdings Ltd. to Report Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 18, 2025

LexinFintech Holdings Ltd. Reports Fourth Quarter and Full Year 2024 Unaudited Financial Results

Ally Financial

American Express

Bread Financial Holdings, Inc. Common Stock

Bread Finl Hldgs

Credit Acceptance Corporation - Common Stock

Credit Acceptance

Capital One Financial Corporation Common Stock

Capital One Finl

Dave

Discover Financial servs

Enova International

EZCORP, Inc. - Class A Non-Voting Common Stock

EZCORP

FirstCash Hldgs

FinVolution Group American Depositary Shares

FinVolution Gr

Joint Stock Company Kaspi.kz - American Depository Shares

Kaspi.kz

LendingClub

Lufax Holding Ltd American Depositary Shares, each representing two (2) Ordinary Shares

Comments

LexinFintech Holdings

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL